Value of M2BP in predicting in‐stent restenosis in patients after coronary drug‐eluting stent implantation

Abstract

Objective We evaluated the association between plasma levels of mac‐2 binding protein (M2BP) with the risk of in‐stent restenosis (ISR) after percutaneous coronary intervention (PCI). Methods Plasma M2BP levels were compared between 258 patients who experienced ISR at 12‐months post‐PCI and 258 patients, matched for age and sex, without angiographic evidence of ISR. Results The plasma M2BP level was significantly higher in the ISR than in the non‐ISR group. On multivariate analysis, adjusted for potential clinical, biochemical, and angiography characteristics, M2BP remained as an independent significant predictor of ISR. Conclusions M2BP may be an important predictive biomarker of ISR and may be useful in identifying at‐risk patients.

A systematic review and bioinformatic study on clinical, paraclinical, and genetic factors predisposing to stent restenosis following percutaneous coronary intervention

“…To assess the main correlates of stent re-stenosis based on applied keywords, in total 67 studies finally assessed that published from different countries between 2004 and 2022 (Table 1). According to our risk of bias assessment, [79] RT-PCR ADRβ2 CDKN1B rs1042713 rs36228499 Yang, 2022 [80] RT-PCR M2BP Liu, 2021 [81] RT-PCR CAMLG GALNT2 C11orf84 THOC5 SAMD11 rs12657663 rs2273970 rs643634 rs737976 rs9988179 Qiu, 2021 [82] Bioinformatics analysis hsa-miR-126-3p PIK3R2 Carretero, 2021 [83] Integrated microarray hsa-miR-30b-5p 62 genes related to vascular remodeling and fibrosis Maheronnaghsh, 2021 [84] Integrated microarray hsa-miR-152-3p Guan, 2018 [85] Integrated microarray hsa-miR − 1 hsa-miR − 21 Zhou, 2017 [86] RT-PCR SOCS1 (gene promoter methylation) Bagyura, 2017 [87] RT-PCR VEGF rs2010963 rs6999447 Zhu, 2017 [88] DNA sequencing A1166C He, 2017 [89] RT-PCR HMGB2 Pleva, 2015 [90] RT-PCR BCHE rs1803274 Li, 2015 [91] RFLP assay A1166C Nozari, 2015 [92] RT-PCR CYP2C19 CYP2C19*2 Liu, 2013 [93] RT-PCR IL-18 -137G/C Gao, 2013 [94] RFLP assay IL-6 -572 C/G Gao, 2011 [95] RFLP assay IL-10 -592 C/A Vogiatzi, 2011 [96] RFLP assay IL-8 -251 A/T 781 C/T Vogiatzi, 2009 [97] RFLP assay RANTES -403G/A Shah, 2008 [98] RFLP assay ALOX5AP RS17222814 RS17216473 RS10507391 Katsaros, 2008 [99] IHC SERPINE1 Wijpkema, 2006 [100] RT-PCR AGTR1 1166 A/C Monraats, 2005 [101] RT-PCR FGB -455G/A anterior descending artery (LAD), and SYNTAX score; and (4) laboratory-based parameters including Higher HbA1c level, higher HsCRP level, raised ApoB, MCV and MCH values, higher neutrophil to lymphocyte ratio, higher apoA-I, higher Homocysteine, higher IgE level, increased lipoprotein-associated phospholipase A2 (Lp-PLA2) and IL-6 levels, higher monocyte count, raised creatinine, raised blood uric acid, lower high-density lipoprotein, higher S100A12 level, higher postoperative homocysteine level, higher VLDL-C, higher PDW, higher BMP-2 level, higher lymphocyte-to-Monocyte Ratio, lower serum albumin, higher white blood cell and neutrophil counts, higher lipoprotein A, higher serum IL-33 serum level, higher serum total bilirubin, higher serum Cystatin C, higher fibrinogen levels, higher serum sLOX-1 level, higher serum IL-6, lower serum IL-10, lower adiponectin levels, higher plasma heparin cofactor II activity, and insulin resistance (Ta...…”